Loading…
Quince Therapeutics, Inc. is projected to rise to $17.64 by 2027, a +1% move from its current price of $17.54. QNCX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $16.90 | $17.54 | $18.21 | +0.02% |
| Jul 14 | $16.65 | $17.55 | $18.49 | +0.03% |
| Jul 15 | $16.45 | $17.55 | $18.72 | +0.05% |
| Jul 16 | $16.29 | $17.55 | $18.91 | +0.06% |
| Jul 17 | $16.15 | $17.55 | $19.08 | +0.08% |
| Jul 18 | $16.03 | $17.56 | $19.23 | +0.09% |
| Jul 19 | $15.91 | $17.56 | $19.38 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $15.91 | $17.56 | $19.38 | +0.11% |
| Week 2 | $15.29 | $17.58 | $20.21 | +0.22% |
| Week 3 | $14.84 | $17.60 | $20.87 | +0.33% |
| Week 4 | $14.47 | $17.62 | $21.45 | +0.44% |
| Week 5 | $14.15 | $17.64 | $21.98 | +0.55% |
| Week 6 | $13.87 | $17.65 | $22.47 | +0.66% |
| Week 7 | $13.62 | $17.67 | $22.94 | +0.77% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions.
The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Quince Therapeutics, Inc. (QNCX) currently trades at a price of $17.23. The market cap stands at $16.85M and the company is ranked 4831 by market capitalization. This provides a sense of the small-cap biotechnology sector segment in which QNCX operates.
A major floor 95.4% below — a decisive break under it would weaken the trend.
The nearest floor, 4.5% below — buyers have tended to step in here.
The nearest ceiling, 33.4% above — a clean break opens room to run.
A major ceiling 68.2% above — clearing it would confirm fresh momentum.
Key QNCX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of QNCX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.35 | Buy | $16.77 | Buy |
| MA 10 | $14.08 | Buy | $14.08 | Buy |
| MA 20 | $7.51 | Buy | $10.01 | Buy |
| MA 50 | $3.69 | Buy | $5.87 | Buy |
| MA 100 | $2.45 | Buy | $6.24 | Buy |
| MA 200 | $12.64 | Buy | $9.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 88.39 | Sell |
| Stoch RSI (14) | 83.36 | Sell |
| CCI (20) | 84.80 | Neutral |
| Williams %R (14) | -3.76 | Info |
| MACD (12,26,9) | 1.31 | Buy |
| ROC (12) | 1711.98 | Buy |
| Bollinger %B (20,2) | 0.81 | Neutral |
| Stochastic %K (14) | 96.24 | Sell |
| TRIX (15) | 17.62 | Buy |
| Awesome (5,34) | 12.49 | Buy |
| Ultimate (7,14,28) | 61.26 | Neutral |
| Momentum (10) | 16.56 | Buy |
| Aroon Osc (25) | 36.00 | Buy |
| Hull MA (9) | 18.37 | Sell |
| ADX (14) | 47.05 | Buy |
| ATR (14) | 0.92 | Info |
The near-term technical picture is labeled BULLISH. The RSI(14) reads 100, indicating a highly energized move on the momentum indicator. The stock’s simple moving averages show SMA50 at $1.75 and SMA200 at $12.60, framing a price path in the context of evolving trendlines. Key levels to watch are support at $0.90 and resistance at $17.23.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.00 | $17.54 | $24.06 | 0% | Neutral | |
| $13.57 | $17.64 | $24.52 | +1% | Neutral | |
| $14.50 | $19.61 | $28.61 | +12% | Neutral | |
| $18.47 | $25.82 | $39.08 | +47% | Bullish | |
| $18.49 | $26.63 | $41.58 | +52% | Bullish | |
| $19.81 | $29.31 | $47.01 | +67% | Bullish | |
| $19.15 | $29.07 | $47.76 | +66% | Bullish | |
| $16.22 | $25.23 | $42.36 | +44% | Bullish | |
| $19.22 | $30.59 | $52.39 | +74% | Bullish | |
| $22.81 | $37.12 | $64.74 | +112% | Bullish | |
| $24.25 | $43.76 | $82.36 | +150% | Bullish | |
| $45.52 | $99.11 | $208.00 | +465% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.00 | $17.54 | $21.44 | +0.00% |
| August 2026 | $15.38 | $18.33 | $22.56 | +4.49% |
| September 2026 | $14.78 | $17.79 | $22.22 | -2.93% |
| October 2026 | $14.35 | $17.41 | $22.02 | -2.14% |
| November 2026 | $14.92 | $18.23 | $23.30 | +4.71% |
| December 2026 | $15.15 | $18.64 | $24.06 | +2.26% |
Click any year to see its month-by-month QNCX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect QNCX to range from $16.00 to $24.06 through 2026. The $17.54 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The QNCX price prediction for 2027 points to an average of $17.64 (low $13.57, high $24.52) — a potential gain of +1% on today's $17.54. Price action looks broadly range-bound.
In 2028, QNCX is projected to trade between $14.50 and $28.61, averaging $19.61 — a potential gain of +12% from today's $17.54. That is up +11% on the projected 2027 average. A consolidation phase looks the most probable path here.
Quince Therapeutics, Inc.'s 2029 outlook centres on $25.82, within a $18.47 to $39.08 range. That is up +32% on the projected 2028 average. That marks a +47% change versus current levels. Momentum favours further upside here.
By 2030, QNCX could reach as high as $41.58, with a base case around $26.63 and support toward $18.49 — roughly +52% from $17.54. Buyers look set to stay in control over this stretch.
Expect QNCX to range from $19.81 to $47.01 through 2031. The $29.31 average target implies a +67% move from current prices. That is up +10% on the projected 2030 average. Momentum favours further upside here.
The QNCX price prediction for 2032 points to an average of $29.07 (low $19.15, high $47.76) — a potential gain of +66% on today's $17.54. Buyers look set to stay in control over this stretch.
In 2033, QNCX is projected to trade between $16.22 and $42.36, averaging $25.23 — a potential gain of +44% from today's $17.54. That is -13% versus the projected 2032 average. Momentum favours further upside here.
Quince Therapeutics, Inc.'s 2034 outlook centres on $30.59, within a $19.22 to $52.39 range. That is up +21% on the projected 2033 average. That marks a +74% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, QNCX could reach as high as $64.74, with a base case around $37.12 and support toward $22.81 — roughly +112% from $17.54. Momentum favours further upside here.
Expect QNCX to range from $24.25 to $82.36 through 2040. The $43.76 average target implies a +150% move from current prices. That is up +18% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The QNCX price prediction for 2050 points to an average of $99.11 (low $45.52, high $208.00) — a potential gain of +465% on today's $17.54. Momentum favours further upside here.
Investing $1,000 in QNCX today (≈ 57.012543 QNCX) could be worth
$5,650.23
+$4,650.23 (+465%) by 2050 · US Dollar
Based on the average projected QNCX price of $99.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in QNCXwould be worth at today's price.
$1,000 invested in QNCX on Jul 10, 2025 (≈ 56.179778 QNCX) would be worth
$985.39
-$14.61 (-1.5%) today · 0.99× · US Dollar
Based on a QNCX entry price of $17.8 vs. today's $17.54.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $17.23 | $1,017.99 | +1.8% |
| 1 month ago | $0.91 | $19,274.72 | +1827.5% |
| 3 months ago | $1.36 | $12,897.06 | +1189.7% |
| 6 months ago | $29.5 | $594.58 | -40.5% |
| 1 year ago | $17.8 | $985.39 | -1.5% |
| All time (5.0y) ago | $586 | $29.93 | -97.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our QNCX forecast.
Our base-case forecast reaches $35.00 around 2035.
Implied market cap at $35.00: $34.23M
Forecasts project a multi-year path with meaningful upside and varied momentum. The 2026 average price is $17.23 with a 0 ROI and NEUTRAL sentiment. The 2027 average price is $18.90 with a 9.7 ROI and NEUTRAL sentiment.
From 2028 onward the outlook strengthens: 2028 avg $25.71 (49.2), 2029 avg $36.56 (112.2), 2030 avg $36.68 (112.9) and 2031 avg $42.05 (144.1). The trajectory continues through 2032 at $40.27 (133.7), 2033 at $32.92 (91.1), 2034 at $50.87 (195.3), and 2035 at $66.75 (287.4), with bullish sentiment. By 2040 the forecast shows an average of $77.63 (350.6) and by 2050 an average of $195.26 (1033.3), both with bullish sentiment.
These figures illustrate substantial potential upside over the long term, though they are estimates and not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $36.68 and a max of $63.72, with a 112.9 ROI and bullish sentiment.
Forecasts indicate potential upside across several years, with an average price rising to $36.68 by 2030 and to $195.26 by 2050, and ROIs including 112.9 (2030), 350.6 (2040), and 1033.3 (2050). These are estimates and not guarantees.
Yes. The 2040 forecast lists a max of $170.49, and the 2050 forecast lists a max of $449.11.
Current price is $17.23 and the market cap is $16.85M.
The 2029 forecast shows an average price of $36.56 and a max of $61.02, with a 112.2 ROI and bullish sentiment.
Quince Therapeutics, Inc. Community Discussion
0Share your Quince Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.